A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/19/6/1068/371279/mdm601.pdf
Reference31 articles.
1. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001
2. Epidermal growth factor receptor: mechanisms of activation and signalling;Jorissen;Exp Cell Res,2003
3. The development of targeted therapy in the ErbB system;Wang,2007
4. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes;Gullick;Br J Cancer,1991
5. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987
Cited by 175 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12
2. Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study;European Journal of Pharmaceutical Sciences;2023-07
3. Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations;Frontiers in Cell and Developmental Biology;2023-04-24
4. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy;Clinical Cancer Research;2022-12-27
5. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions;Cancer Research;2022-06-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3